In a recent ruling, the Federal Court of Appeal (FCA) denied the motion by Janssen Inc., which sought a judicial review of the Office of Submissions and Intellectual Property’s (OSIP) refusal to list the Canadian Patent No. 3,113,837 on the Patent Register. This decision centers around two supplementary new drug submissions (SNDSs) for Janssen’s STELARA (ustekinumab).
The OSIP’s decision to disallow the patent listing against STELARA SNDSs previously raised questions around their grounds for refusal. Despite Janssen’s subsequent appeal, the court upheld the original OSIP judgement, supporting the notion that the patent in discussion was indeed not listable.
This dismissal of appeal will inevitably incite debate among legal professionals, especially those specialising in intellectual property laws. The case highlights the delicate balance between fostering innovation in the healthcare sector and ensuring market competition. It underscores the challenges pharmaceutical companies face when they attempt to extend patent protection for their drug developments.
Further nuances and implications of this legal precedent are detailed in the original text of the ruling, which is available here.
As the need for clearer guidelines and more predictable outcomes in patent listing proceedings becomes apparent, ongoing legal scrutiny will play a significant role in shaping this policy area. For corporations and law firms alike, understanding the evolving judicial landscape is crucial—especially in rapidly developing sectors like healthcare and pharmaceuticals.